Challenges in translating plasma proteomics from bench to bedside: Update from the NHLBI Clinical Proteomics Programs

Robert E. Gerszten, Frank Accurso, Gordon R. Bernard, Richard M. Caprioli, Eric W Klee, George G. Klee, Iftikhar Jan Kullo, Theresa A. Laguna, Frederick P. Roth, Marc Sabatine, Pothur Srinivas, Thomas J. Wang, Lorraine B. Ware

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The emerging scientific field of proteomics encompasses the identification, characterization, and quantification of the protein content or proteome of whole cells, tissues, or body fluids. The potential for proteomic technologies to identify and quantify novel proteins in the plasma that can function as biomarkers of the presence or severity of clinical disease states holds great promise for clinical use. However, there are many challenges in translating plasma proteomics from bench to bedside, and relatively few plasma biomarkers have successfully transitioned from proteomic discovery to routine clinical use. Key barriers to this translation include the need for "orthogonal" biomarkers (i.e., uncorrelated with existing markers), the complexity of the proteome in biological samples, the presence of high abundance proteins such as albumin in biological samples that hinder detection of low abundance proteins, false positive associations that occur with analysis of high dimensional datasets, and the limited understanding of the effects of growth, development, and age on the normal plasma proteome. Strategies to overcome these challenges are discussed.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume295
Issue number1
DOIs
StatePublished - Jul 2008

Fingerprint

National Heart, Lung, and Blood Institute (U.S.)
Proteomics
Proteome
Biomarkers
Proteins
Body Fluids
Growth and Development
Blood Proteins
Albumins
Technology

Keywords

  • Protein content
  • Proteome

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology
  • Physiology

Cite this

Challenges in translating plasma proteomics from bench to bedside : Update from the NHLBI Clinical Proteomics Programs. / Gerszten, Robert E.; Accurso, Frank; Bernard, Gordon R.; Caprioli, Richard M.; Klee, Eric W; Klee, George G.; Kullo, Iftikhar Jan; Laguna, Theresa A.; Roth, Frederick P.; Sabatine, Marc; Srinivas, Pothur; Wang, Thomas J.; Ware, Lorraine B.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 295, No. 1, 07.2008.

Research output: Contribution to journalArticle

Gerszten, Robert E. ; Accurso, Frank ; Bernard, Gordon R. ; Caprioli, Richard M. ; Klee, Eric W ; Klee, George G. ; Kullo, Iftikhar Jan ; Laguna, Theresa A. ; Roth, Frederick P. ; Sabatine, Marc ; Srinivas, Pothur ; Wang, Thomas J. ; Ware, Lorraine B. / Challenges in translating plasma proteomics from bench to bedside : Update from the NHLBI Clinical Proteomics Programs. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2008 ; Vol. 295, No. 1.
@article{b5a9d65f706540c79443a27eefec42b6,
title = "Challenges in translating plasma proteomics from bench to bedside: Update from the NHLBI Clinical Proteomics Programs",
abstract = "The emerging scientific field of proteomics encompasses the identification, characterization, and quantification of the protein content or proteome of whole cells, tissues, or body fluids. The potential for proteomic technologies to identify and quantify novel proteins in the plasma that can function as biomarkers of the presence or severity of clinical disease states holds great promise for clinical use. However, there are many challenges in translating plasma proteomics from bench to bedside, and relatively few plasma biomarkers have successfully transitioned from proteomic discovery to routine clinical use. Key barriers to this translation include the need for {"}orthogonal{"} biomarkers (i.e., uncorrelated with existing markers), the complexity of the proteome in biological samples, the presence of high abundance proteins such as albumin in biological samples that hinder detection of low abundance proteins, false positive associations that occur with analysis of high dimensional datasets, and the limited understanding of the effects of growth, development, and age on the normal plasma proteome. Strategies to overcome these challenges are discussed.",
keywords = "Protein content, Proteome",
author = "Gerszten, {Robert E.} and Frank Accurso and Bernard, {Gordon R.} and Caprioli, {Richard M.} and Klee, {Eric W} and Klee, {George G.} and Kullo, {Iftikhar Jan} and Laguna, {Theresa A.} and Roth, {Frederick P.} and Marc Sabatine and Pothur Srinivas and Wang, {Thomas J.} and Ware, {Lorraine B.}",
year = "2008",
month = "7",
doi = "10.1152/ajplung.00044.2008",
language = "English (US)",
volume = "295",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Challenges in translating plasma proteomics from bench to bedside

T2 - Update from the NHLBI Clinical Proteomics Programs

AU - Gerszten, Robert E.

AU - Accurso, Frank

AU - Bernard, Gordon R.

AU - Caprioli, Richard M.

AU - Klee, Eric W

AU - Klee, George G.

AU - Kullo, Iftikhar Jan

AU - Laguna, Theresa A.

AU - Roth, Frederick P.

AU - Sabatine, Marc

AU - Srinivas, Pothur

AU - Wang, Thomas J.

AU - Ware, Lorraine B.

PY - 2008/7

Y1 - 2008/7

N2 - The emerging scientific field of proteomics encompasses the identification, characterization, and quantification of the protein content or proteome of whole cells, tissues, or body fluids. The potential for proteomic technologies to identify and quantify novel proteins in the plasma that can function as biomarkers of the presence or severity of clinical disease states holds great promise for clinical use. However, there are many challenges in translating plasma proteomics from bench to bedside, and relatively few plasma biomarkers have successfully transitioned from proteomic discovery to routine clinical use. Key barriers to this translation include the need for "orthogonal" biomarkers (i.e., uncorrelated with existing markers), the complexity of the proteome in biological samples, the presence of high abundance proteins such as albumin in biological samples that hinder detection of low abundance proteins, false positive associations that occur with analysis of high dimensional datasets, and the limited understanding of the effects of growth, development, and age on the normal plasma proteome. Strategies to overcome these challenges are discussed.

AB - The emerging scientific field of proteomics encompasses the identification, characterization, and quantification of the protein content or proteome of whole cells, tissues, or body fluids. The potential for proteomic technologies to identify and quantify novel proteins in the plasma that can function as biomarkers of the presence or severity of clinical disease states holds great promise for clinical use. However, there are many challenges in translating plasma proteomics from bench to bedside, and relatively few plasma biomarkers have successfully transitioned from proteomic discovery to routine clinical use. Key barriers to this translation include the need for "orthogonal" biomarkers (i.e., uncorrelated with existing markers), the complexity of the proteome in biological samples, the presence of high abundance proteins such as albumin in biological samples that hinder detection of low abundance proteins, false positive associations that occur with analysis of high dimensional datasets, and the limited understanding of the effects of growth, development, and age on the normal plasma proteome. Strategies to overcome these challenges are discussed.

KW - Protein content

KW - Proteome

UR - http://www.scopus.com/inward/record.url?scp=49049098527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49049098527&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00044.2008

DO - 10.1152/ajplung.00044.2008

M3 - Article

C2 - 18456800

AN - SCOPUS:49049098527

VL - 295

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 1

ER -